These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 10770461)

  • 1. Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia.
    Grothe DR; Calis KA; Jacobsen L; Kumra S; DeVane CL; Rapoport JL; Bergstrom RF; Kurtz DL
    J Clin Psychopharmacol; 2000 Apr; 20(2):220-5. PubMed ID: 10770461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olanzapine treatment in chronic drug-resistant childhood-onset schizophrenia: an open-label study.
    Mozes T; Greenberg Y; Spivak B; Tyano S; Weizman A; Mester R
    J Child Adolesc Psychopharmacol; 2003; 13(3):311-7. PubMed ID: 14642019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral olanzapine disposition in adolescents with schizophrenia or bipolar I disorder: a population pharmacokinetic model.
    Lobo ED; Robertson-Plouch C; Quinlan T; Hong Q; Bergstrom RF
    Paediatr Drugs; 2010 Jun; 12(3):201-11. PubMed ID: 20297865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal dose of risperidone and olanzapine for patients with schizophrenia in Taiwan.
    Liu CY; Chiu NY; Wu CK; Yuan LM; Hsiao MC; Liao O
    Int Clin Psychopharmacol; 2003 Jan; 18(1):49-51. PubMed ID: 12490775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olanzapine. Pharmacokinetic and pharmacodynamic profile.
    Callaghan JT; Bergstrom RF; Ptak LR; Beasley CM
    Clin Pharmacokinet; 1999 Sep; 37(3):177-93. PubMed ID: 10511917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dissolution profile, tolerability, and acceptability of the orally disintegrating olanzapine tablet in patients with schizophrenia.
    Chue P; Jones B; Taylor CC; Dickson R
    Can J Psychiatry; 2002 Oct; 47(8):771-4. PubMed ID: 12420656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. D2 receptor occupancy under recommended and high doses of olanzapine.
    Harvey EJ; Taylor DM; Flanagan RJ
    J Psychopharmacol; 2001 Sep; 15(3):213-4. PubMed ID: 11565632
    [No Abstract]   [Full Text] [Related]  

  • 8. Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia.
    Mitchell M; Kothare P; Bergstrom R; Zhao F; Jen KY; Walker D; Johnson J; McDonnell D
    Clin Ther; 2013 Dec; 35(12):1890-908. PubMed ID: 24184052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of fluoxetine on olanzapine pharmacokinetics.
    Gossen D; de Suray JM; Vandenhende F; Onkelinx C; Gangji D
    AAPS PharmSci; 2002; 4(2):E11. PubMed ID: 12102620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
    Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; Chakos M; McEvoy JP
    J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mnestic impairment under olanzapine overdosage in an elderly patient].
    Grieshaber S; Jatzko A; Adler G
    Psychiatr Prax; 2002 Nov; 29(8):441-4. PubMed ID: 12436366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of childhood-onset schizophrenia with olanzapine.
    Sholevar EH; Baron DA; Hardie TL
    J Child Adolesc Psychopharmacol; 2000; 10(2):69-78. PubMed ID: 10933117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Dose, Age, Sex, Body Weight, and Smoking on Plasma Concentrations of Olanzapine and N-desmethyl Olanzapine in Inpatients With Schizophrenia.
    An H; Fan H; Chen S; Qi S; Ma B; Shi J; Wang Z; Yang F
    J Clin Psychopharmacol; 2021 May-Jun 01; 41(3):255-259. PubMed ID: 33814547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of antipsychotic drugs.
    Meibach RC
    Am J Psychiatry; 2003 Mar; 160(3):589-90; author reply 592-3. PubMed ID: 12611851
    [No Abstract]   [Full Text] [Related]  

  • 15. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.
    Breier A; Meehan K; Birkett M; David S; Ferchland I; Sutton V; Taylor CC; Palmer R; Dossenbach M; Kiesler G; Brook S; Wright P
    Arch Gen Psychiatry; 2002 May; 59(5):441-8. PubMed ID: 11982448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.
    Simpson MM; Goetz RR; Devlin MJ; Goetz SA; Walsh BT
    J Clin Psychiatry; 2001 Sep; 62(9):694-700. PubMed ID: 11681765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Schizophrenia and schizoaffective disorder treated with high doses of olanzapine.
    Fanous A; Lindenmayer JP
    J Clin Psychopharmacol; 1999 Jun; 19(3):275-6. PubMed ID: 10350037
    [No Abstract]   [Full Text] [Related]  

  • 18. Differential olanzapine plasma concentrations by sex in a fixed-dose study.
    Kelly DL; Conley RR; Tamminga CA
    Schizophr Res; 1999 Nov; 40(2):101-4. PubMed ID: 10593449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose olanzapine and prolactin levels.
    Karagianis JL; Baksh A
    J Clin Psychiatry; 2003 Oct; 64(10):1192-4. PubMed ID: 14658967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
    Martín J; Gómez JC; García-Bernardo E; Cuesta M; Alvarez E; Gurpegui M
    J Clin Psychiatry; 1997 Nov; 58(11):479-83. PubMed ID: 9413413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.